Developing a Nanobody to Target the Interleukin-31 Receptor as a Treatment for Atopic Dermatitis
The Oxford Journal of Student Scholarship · 2026-10
DOI: 10.65161/recpgxnolplhey2uh ↗Kurz gefasst
Fachartikel in der Zeitschrift The Oxford Journal of Student Scholarship, 2026-10. Verfasst von Preetika Kaur.
Abstract (Originalsprache)
Atopic Dermatitis (AD), the most common form of eczema, causes chronic pruritus, regularly disrupting sleep, work, and other essential activities.Over 50% of adults with AD have found treatments to be ineffective.This research seeks to computationally design an effective yet non-invasive treatment for AD for future in-vivo testing.One of the major signaling molecules in the AD pathogenesis pathway is the cytokine interleukin-31 (IL-31).Treatments for AD targeting the IL-31 receptor exist, however these are monoclonal antibody treatments and require administration via injection.This can be avoided with a smaller therapeutic, like a nanobody, which could be equally effective while having more accessible administration methods.The structure of the IL-31A subunit was obtained and used in a protein generating software.Multiple different trials specified different binding areas to design nanobodies with both similar, and dissimilar epitopes to nemolizumab, an existing monoclonal antibody treatment.Generation was run in batches of 50, with the top 10 designs based on overall quality being returned for analysis.ipTM scores, design pTM scores, along with buried surface area (BSA) and other measures, were manually calculated and collected.After comparison to the same values in nemolizumab, the overall top design showed similarities suggesting high likelihood of in-vivo success.The ipTM value was below 0.6, so for future studies this design could be improved before in-vivo testing to increase chances of in-vivo success.These results, combined with nanobodies' ease of administration via hydrogel-forming microneedle patches, provide the foundation for a new AD therapeutic.
Zitieren
APA
Kaur, P. (2026). Developing a Nanobody to Target the Interleukin-31 Receptor as a Treatment for Atopic Dermatitis. The Oxford Journal of Student Scholarship. https://doi.org/10.65161/recpgxnolplhey2uh
Vancouver
Kaur P. Developing a Nanobody to Target the Interleukin-31 Receptor as a Treatment for Atopic Dermatitis. The Oxford Journal of Student Scholarship. 2026. doi:10.65161/recpgxnolplhey2uh
BibTeX
@article{Kaur2026,
author = {Kaur, Preetika},
title = {Developing a Nanobody to Target the Interleukin-31 Receptor as a Treatment for Atopic Dermatitis},
journal = {The Oxford Journal of Student Scholarship},
year = {2026},
doi = {10.65161/recpgxnolplhey2uh}
}
EUVIMED